expression levels of protein-coding genes have been reported in several independent studies. [3] [4] [5] [6] Most of these investigations identified relatively few genes that were significantly differentially expressed between CHD cases and controls, and there is little overlap among the genes identified. The failure to identify replicable CHD gene signatures may reflect the small effect sizes and complexity of differentially expressed genes in CHD. By using an integrative network analysis strategy, we recently identified a coexpression network module that we suspect of being causally associated with CHD. 7 MicroRNAs (miRNAs), a class of small noncoding RNAs, represent an important mediator of post-transcriptional regulation of mRNA expression or mRNA translation into proteins. [8] [9] [10] The importance of miRNAs in cardiovascular disorders is becoming increasingly recognized. Highly specific miRNA expression patterns have been correlated with different cardiovascular disorders, 11 such as heart failure (HF), [12] [13] [14] myocardial infarction, 15 and vascular remodeling. 11 Despite several early successes identifying molecular underpinnings of CHD at the levels of genetic sequence and of mRNA and miRNA expression, the relationships between these 3 molecular elements and their multidimensional interactions in relation to CHD susceptibility remain largely unknown. Recent studies have revealed that mRNA and miRNA transcript levels behave as heritable quantitative traits and display significant association with genetic variation. [16] [17] [18] [19] [20] The association of single-nucleotide polymorphisms (SNPs) with the expression of mRNAs or miRNAs has been proposed as a mechanism that can affect disease risk and drug treatment response because mRNA (or miRNA) expression-associated SNPs (eSNPs) affect gene expression or miRNA targeting affinity. 21 Given the complexity of the molecular underpinnings of complex diseases, such as CHD, which is likely to be due in part to disrupted heterotypic SNP-miRNA-mRNA associations, integrative genomic analyses that incorporate all 3 dimensions of molecular data are necessary to investigate and characterize the complex changes in the regulatory machinery and their effects on biological functions and disease risks.
To this end, we assayed miRNA expression in 186 CHD cases and 186 age, sex, and statin treatment-matched controls from the Framingham Heart Study (FHS) and integrated miRNA profiling with SNP and mRNA expression data from the same individuals. Using an integrative analysis framework that used these comprehensive genome-wide resources ( Figure 1) , we examined the complex multidimensional SNP-miRNA-mRNA relationships in the context of CHD. At first, we sought to establish links between genome-wide associations of genetic variants with miRNA and mRNA expression by identifying miRNA eSNPs, mRNA eSNPs, and miRNA-mRNA coexpression pairs ( Figure 1A) . Second, we sought to find molecular associations between SNPs, miRNAs, and mRNAs in relation to CHD status ( Figure 1B) . We identified differentially expressed miRNAs (miRNA signatures) associated with CHD, differential miRNA-mRNA coexpression pairs in relation to CHD, and miRNAs associated with mRNA differential coexpression modules in the context of CHD. These CHD-related miRNAs and mRNAs were, in turn, integrated with results from CHD GWAS 1 and with eSNPs, to determine inferentially, which transcriptomic differences were putatively causal for CHD and which were downstream responses to CHD. In this way, we dissected the role of miRNAs in regulating gene networks associated with CHD.
Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
Results

Demographics of the Study Population
We designed a CHD case-control study consisting of prevalent CHD cases and age, sex, and statin use-matched controls in the FHS. In 2 recent reports, 3,7 we explored differential mRNA expression and derived gene networks associated with CHD in 188 case-control pairs. Among the 188 pairs, 186 pairs had successful miRNA profiling and were used in subsequent analyses. The clinical characteristics of the 186 CHD case-control pairs are described in Table I in the online-only Data Supplement.
Influence of Blood Cell Types on CHD-Associated miRNA Expression Differences
As miRNA expression levels might be influenced by differences in the proportions of different cell types in whole blood, we assessed the correlations between miRNAs and cell type proportions imputed from whole blood mRNA expression (Materials and Methods in the online-only Data Supplement). At false discovery rate (FDR) <0.05, 20 miRNAs showed significant correlations with ≥1 of the 7 cell types ( Table II in the online-only Data Supplement). This analysis suggested that cell type proportions affect only a small fraction of miRNAs. The remaining majority of miRNAs may reflect signals relatively independent of cell types. However, we cannot exclude the possibility of small cell type effects. Therefore, we carried out 2 sets of analysis: one using cell count-adjusted miRNA data and the other using unadjusted data. Adjusting for cell counts did not have a major influence on our results. Therefore, in the subsequent sections, we focus on results from the unadjusted analysis but also report differences if any were observed.
Identification of Differentially Expressed miRNAs Between CHD Cases and Controls
Among the 752 miRNAs assayed, 271 miRNAs were expressed in >50 individuals and were used for differential 13 ; miR-422a was reported to be expressed in both monocytes and atherosclerotic plaques. 22 Analysis of miRNA data from 3 previously published studies revealed associations with cardiovascular disease for miR-191, 13 miR-589, 13 miR-423-5p, 13, 23 miR-339-3p, 23 miR-422a, 23, 24 miR-425, 23 miR-500, 23 and miR-550 24 at P<0.05 in plasma 13, 23 or platelets. 24 To our knowledge, the other miRNA signatures that we identified have not been reported previously in relation to CHD.
Identification of miRNA Regulatory SNPs (miR-eSNPs)
To gain insight into genetic regulation of miRNAs, we analyzed the associations between genome-wide SNP genotypes and miRNA expression by pooling CHD cases and controls together (n=361). At FDR<0.05, we identified 123 cis-miR-eSNPs for 13 miRNAs (the full list is provided in Table III in the online-only Data Supplement; the top cis-miR-eSNPs are reported in Table 2 ). Among the top signals in Table 2 , miR-100 and miR-125 had 2 cis-miR-eSNPs (rs10750218 and rs11218891) that overlapped with those identified by Borel et al 20 for the same miRNAs, supporting the reliability of the cissignals identified in our study. This finding also supports the notion that miRNAs have their own cis-regulatory elements. rs7941030, a cis-miR-eSNP for both miR-100 (P=3.7×10 −6 ) and miR-125 (P=1.9×10 −5 ), was previously found to be associated with high-density lipoprotein cholesterol and total cholesterol in genome-wide association testing. 25 Among these cis-miR-eSNPs, 72% are located in the 5′-upstream region, suggesting that these miR-eSNPs may regulate miRNA expression by perturbing the regulatory regions of miRNAs. We did not find any cis-miR-eSNPs in the seed regions of the miRNAs.
As miR-eSNPs that affect miRNA expression may in turn affect their target mRNAs, we compared the cis-miR-eSNPs identified in this study with the mRNA-eSNPs identified in the same individuals in our previous study. 7 In doing so, we found little overlap (overlapping eSNPs are listed in Table IV in the online-only Data Supplement). Considering that cis-miR-eSNPs are likely trans-mRNA-eSNPs, whereas trans-eSNPs are difficult to detect, we speculate that the lack of overlap between the mRNA and miRNA eSNPs might result from the fact that a large proportion of SNP-miRNA associations were not detectable given the moderate sample size of our study. Integrative genomic analysis framework depicting the genome-wide evaluation of the relationships between single-nucleotide polymorphisms (SNPs), miRNAs and mRNAs and the identification of coronary heart disease (CHD)-related signals. A, Genome-wide evaluation of SNP-miRNA-mRNA associations. The genome-wide evaluation includes the identification of mRNA/ miRNA expression-associated SNPs (eSNPs) and miRNA-mRNA expression pairs. B, Identification of CHD-related molecular relationships in CHD casecontrol samples. The overall analysis includes 5 steps. First, identification of CHD differential mRNA signatures and mRNA coexpression module (this step and results were reported in our previous paper 7 ). Second, identification of differentially expressed miRNA signatures in CHD vs controls. Third, identification of miRNA-mRNA coexpression patterns in CHD cases and controls, and then identification of differential miRNA-mRNA coexpression pairs between the 2 groups. Fourth, identification of miRNAs correlated with a CHD differential mRNA coexpression module. Fifth, integration of the CHD miRNA and mRNA sets identified in steps 1 to 4 with CHD genome-wide association studies (GWAS), as well as miRNA and mRNA-eSNPs by the SNP set enrichment method, 35 to assess the directionality of causality.
Identification of CHD-Related miRNA-mRNA Coexpression Pairs
To further explore the regulatory mechanisms involving miRNAs in CHD, we performed association analysis between miRNAs and mRNAs. At FDR<0.05, we identified 5539 miRNA-mRNA coexpression pairs in the CHD case group, 6558 pairs in the control group, and 26 115 pairs in the pooled sample (Table V and Figure II in the online-only Data  Supplement) . These results support the existence of extensive associations between miRNAs and mRNAs.
There were 691 miRNA-mRNA coexpression pairs common to the CHD case and control groups (Figure 2A ), and all of these pairs showed consistent directions in their correlation coefficients ( Figure 2B ). The genes in this consistent set of miRNA-mRNA pairs were found to be enriched for intracellular transport (Bonferroni correction [BF] P=3.6×10 −10 ) and cellular protein localization (BF P=1.2×10 −6 ; Table 3 ). This set most likely reflects the common regulatory relationships between miRNA and mRNA under different physiological or pathological conditions. Importantly, 80% of the miRNA-mRNA coexpression pairs in CHD cases were inversely correlated ( Figure 2C ), whereas only 30% of the miRNA-mRNA coexpression pairs in controls were inversely correlated ( Figure 2D ). The directional shift in miRNA-mRNA coexpression between CHD cases and controls was highly significant (P<1×10 −16 by proportions test 26 ). This major shift toward negative correlation in CHD cases, coupled with our finding that CHD miRNA differential signatures were all upregulated in cases, suggested that the widespread upregulation of miRNAs in cases might either play an important role in the pathogenesis of CHD by inhibiting mRNA expression levels of genes protective of CHD or function reactively to inhibit CHD-related mRNA expression. When we adjusted for whole blood cell counts, we observed even more striking differences in the correlated miRNA-mRNA pairs between CHD cases (85% inversely correlated) and controls (15% inversely correlated). We further defined 1472 case-specific and 1325 controlspecific miRNA-mRNA coexpression pairs, by requiring the miRNA-mRNA pairs to be coexpressed in one group at FDR<0.05 but not in the other, and to show significant miRNA-mRNA interactions with regard to CHD status at FDR<0.2 (Table VI in the online-only Data Supplement). Gene ontology enrichment analysis (Table 3) revealed that the case-specific coexpression set is enriched for genes involved in intracellular transport (BF, P=2.6×10 −4 ) and gene silencing by RNA (BF, P=0.01). In contrast, the controlspecific coexpression set is enriched for genes involved in the M phase of the mitotic cell cycle (BF, P=1.6×10 −3 ) and nuclear division (BF, P=3.9×10 −3 ). We hypothesize that these case-specific and control-specific coexpression pairs reflect the different miRNA-mRNA regulatory patterns observed under pathological (ie, CHD) and physiological (ie, control) conditions, and therefore, might be relevant to the pathogenesis of CHD.
Validation of the Differential miRNA-mRNA Coexpression Patterns Between CHD Cases and Controls
To validate the observation of a higher proportion of inversely correlated miRNA-mRNA pairs in cases versus controls, we used 2 approaches: (1) a resampling strategy within the casecontrol study and (2) replication in separate CHD cases and controls in the FHS (n=63 cases and 1000 controls) that did not overlap with the original case-control sets.
Validation Through Resampling
We randomly sampled 80% of CHD cases and controls to calculate miRNA-mRNA coexpression and repeated this process 100 times. For each resampling set, we identified significant miRNA-mRNA coexpression pairs at FDR<0.05 (miRNA and mRNA correlation analysis) and compared the average proportion of inversely correlated miRNA-mRNA pairs separately in CHD cases and controls. The average proportion of inversely correlated miRNA-mRNA pairs was 0.76 in CHD cases and 0.25 in Figure 3A) . Therefore, the observed trend was robust in subpopulations of the case-control study and was not driven by spurious subsets of individuals.
Independent Validation
We were unable to identify any external cohorts with miRNA and mRNA expression data for CHD cases and controls. However, through additional follow-up, we identified 63 additional prevalent CHD cases and 1000 controls in the FHS. These individuals did not overlap with those included in our case-control study and were used as independent replication samples. The clinical characteristics of these replication samples are provided in Table VII in the online-only Data Supplement.
To validate the observed higher proportion of positively correlated miRNA-mRNA pairs in controls (versus cases), we selected 1000 individuals free of CHD who did not share familial relatedness. At FDR cutoffs of 1×10 −3 (4701 pairs) and 1×10 −4 (1487 pairs), with the number of coexpression pairs at a scale comparable with those in the case-control study, the proportions of positively correlated miRNA-mRNA pairs were 66% and 73%, respectively. We also found that the Pearson correlation coefficients of the miRNA-mRNA pairs among the 186 controls from our case-control study were highly consistent with those in the 1000 replication controls at P<1×10 −16 by linear regression testing. These results support the reproducibility of the observed trend of positive correlation of miRNA-mRNA coexpression pairs among controls.
Because of the small number of CHD cases (n=63) in the replication set, statistical power was low to detect significant miRNA-mRNA correlations. In fact, only 5 significant miRNA-mRNA coexpression pairs in the additional CHD cases were identified at FDR<0.05, precluding a direct comparison of significant miRNA-mRNA coexpression in this replication set with that from the 186 CHD cases in the casecontrol study using the same statistical cutoff. As an alternative strategy, we examined whether the directionality (positive or negative) of the miRNA-mRNA coexpression pairs identified in the original 186 CHD cases at FDR<0.05 was consistent in the 63 replication CHD cases. The Pearson coefficients of the miRNA-mRNA pairs between the 186 CHD cases and the 63 replication CHD cases were found to be highly consistent (P<1×10 −16 by linear regression testing). Among the pairs that passed P<0.05 and showed consistency in directionality in the replication CHD set, the proportion of inversely correlated mRNA-miRNA pairs was 70% (101 positively and 238 inversely correlated pairs; Figure 3B ). These results support the original miRNA-mRNA coexpression pattern observed in the CHD cases.
Target Relationships Between miRNAs and mRNAs Within the Coexpression Pairs
We overlapped the miRNA-mRNA coexpression pairs identified in our study with the miRNA-mRNA target pairs curated from 6 miRNA databases [27] [28] [29] [30] [31] [32] and found that 10% of the coexpression pairs overlapped with the predicted target pairs. We further investigated whether cis-eSNPs of the mRNAs in the coexpression pairs disrupt miRNA target sites. Of the 57 847 cis-mRNA-eSNPs, 34 195 could be mapped to mRNAs within the 9267 miRNA-mRNA coexpression pairs. For each eSNP, we extracted a genomic sequence of 13 bases surrounding the SNP. Then, we used TargetScan 33, 34 to scan each sequence for potential miRNA target sites of the corresponding coexpressed miRNA. We identified 134 miRNA target site eSNPs for 172 predicted miRNA-mRNA target associations that were also coexpression pairs ( Table VIII in the online-only Data Supplement). Among the cis-mRNA-eSNPs located in miRNA target sites, 11 were mapped to miR-423-5p, miR-425-3p, miR-502-3p and miR-505-5p, which appeared among the top CHD miRNA signatures (Table 1) . These results support the regulator-target relationships for a subset of miRNA-mRNA coexpression pairs. However, coexpression between miRNA and mRNA does not have to be a regulator-target relationship in nature but may simply reflect coregulation of functionally related miRNAs and mRNAs by internal or external factors. Indeed, the gene ontology enrichment analysis (Table 3 ) revealed that the case-and control-specific miRNA-mRNA coexpressed pairs are enriched for genes involved in specific biological functions and pathways.
Testing Whether the CHD-Associated miRNA Signatures and miRNA-mRNA Coexpression Pairs Are Potentially Causal for CHD
The above analyses identified differentially expressed miRNA signatures of CHD and CHD case-specific or control-specific miRNA-mRNA coexpression pairs. We used SNP set enrichment analysis 35 to test if any of these 3 gene sets are putatively causal for CHD by showing enrichment with low P value CHD SNPs from the Coronary ARteryDIsease Genome wide Replication and Meta-analysis Consortium (CARDIoGRAM) GWAS. 1 If the representative miR-eSNPs from a gene set showed CHD genetic risk enrichment, we termed the gene set putatively causal via miRNAs, and if the representative mRNA-eSNPs of a gene set showed CHD genetic signal enrichment, we termed the gene set putatively causal via mRNAs.
When only the 123 cis-miR-eSNPs identified in the current case-control study were used in the analysis, there were no mRNA or miRNA sets found to be putatively causal via miRNAs (data not shown), which could result from a lack of statistical power when the number of eSNPs is small. To address this possibility, we repeated this analysis by using another miR-eSNP resource consisting of ≈6000 cis-miR-eSNPs that we identified from whole blood-derived miRNA from 5329 FHS participants (details are given in the Materials and Methods in the online-only Data Supplement). All the cis-miR-eSNPs in the case-control pairs were also identified as cis-miR-eSNPs in the larger sample of 5329 participants, supporting the reliability of the cis-miR-eSNPs. When the ≈6000 cis-miR-eSNPs were used, the representative cis-miR-eSNPs from case-specific miRNA-mRNA coexpression pairs showed significant enrichment for CHD GWAS SNPs using both the Kolmogorov-Smirnov test (P=0.03) and Fisher exact test (P=3.3×10 −6 ; Table 4 ), supporting the hypothesis that CHD-related genetic variations may first perturb the expression levels of miRNAs in the case-specific miRNA-mRNA coexpression pairs, which in turn is associated with CHD. When examining individual miRNAs within the casespecific coexpression pairs and their cis-miR-eSNPs in relation to CHD, we found 172 cis-miR-eSNPs at P<0.05 in the CARDIoGRAM CHD GWAS 1 ( Table IX in In contrast, the control-specific miRNA-mRNA coexpression pairs were found to be putatively causal via mRNAs (P=2.1×10 −23 by Kolmogorov-Smirnov test and P=7.2×10 −59 by Fisher exact test; Table 4 ). Among genes in the controlspecific miRNA-mRNA coexpression pairs, 1129 eSNPs for 130 mRNAs were associated with CHD at P<0.05 in CARDIoGRAM 1 (194 eSNPs of 11 genes were associated with CHD at P<1×10 −3 ; Table X in the online-only Data Supplement). These results suggest that the differential miRNA-mRNA coexpression patterns between CHD cases and controls might be driven by eSNPs that disturb either miRNA or mRNA expression.
Association of miRNAs With a Previously Identified Gene Coexpression Module Tested Causal for CHD
In our previous study, we identified a CHD causal mRNA coexpression module using systems network approaches. 7 The genes in the CHD causal module showed a coexpression pattern in controls, but the coexpression was disrupted in CHD cases. This CHD mRNA module was enriched for genes related to B-cell activation and differentiation processes and also tested putatively causal for lipid regulation and CHD. In addition, we identified 63 key drivers that seemed to regulate the module genes.
To test whether any miRNAs are related to the CHD mRNA module, we retrieved the first principle component of this module and correlated the principle component with every miRNA expression trait. Three miRNAs (miR-1275, miR-365a-3p, and miR-150-5p) showed significant correlation with the module principle component at FDR<0.2 ( Table 5 ), suggesting that these 3 miRNAs may participate in B-cell activation and differentiation processes along with the module genes. Eight genes within the module and their key drivers were predicted mRNA targets of these 3 miRNAs, 31 among which 5 genes (ARHGAP24, BTLA, DENND5B, MOBKL2B, and POU2AF1) are potential miR-150-5p targets 31 and 3 genes (PAX5, POU2AF1, and BTLA) are related to B-cell developmental regulation. 36, 37 In addition, 9 differentially expressed miRNA signatures of CHD (eg, miR-1275, miR-589-3p, and miR-324-5p) were predicted to target 17 mRNAs within the CHD causal module or key drivers (Table XI in the online-only Data Supplement). The role of miR-1275 in the context of CHD is particularly interesting because this miRNA was strongly correlated with the CHD mRNA causal module (P=8.2×10 −6 ) and also showed significant differential expression in relation to CHD status (P=0.009).
Discussion
Although the importance of miRNAs in cardiovascular development and disease is becoming increasingly recognized, the relationships of miRNAs with CHD have been analyzed only in a few studies. [12] [13] [14] [15] 22 In this study, genome-wide genotyping and miRNA and mRNA expression profiling analysis were performed on 186 CHD case-control pairs. Using systems biology approaches, we explored the genetic architecture of miRNA regulation and investigated differential miRNA expression and differential miRNA-mRNA correlation between cases and controls, seeking to delineate gene regulatory networks capturing complex DNA-miRNA-mRNA relationships that may contribute to CHD. To our knowledge, our study is the first comprehensive interrogation of CHD to integrate multidimensional molecular data, including genetic variation, mRNA, and miRNA in a large community-based cohort. Our study yielded important evidence supporting the genetic control of miRNAs, as well as an important role of miRNAs in CHD development.
To dissect the genetic elements and mechanisms governing miRNA expression, we conducted expression quantitative trait locus analysis to identify miR-eSNPs. In contrast to more extensive investigations of mRNA-eSNPs in multiple tissues, such as blood, 16, 38 adipose, 16 and liver, 17 there are relatively few studies of miR-eSNPs and most involve small sample sizes. 19, 20, 39 For example, one study using umbilical cord blood from 180 newborns identified only 12 cis-miR-eSNPs at FDR<0.5. 20 In another investigation, no cis-miR-eSNPs were identified in 176 lymphoblastoid cell lines from CEU (Central European) and YRI (Yoruba in Ibadan, Nigeria) cohorts. 19 Our study represents the largest sample size (n=361) studied to date, and we identified 123 cis-miR-eSNPs for 13 miRNAs at FDR<0.05. Two of the cis-miR-eSNPs (for miR-100 and miR-125) that we detected overlap with those identified by Borel et al, 20 reflecting independent external replication. All 123 cis-miR-eSNPs were replicated in a larger study of >5000 individuals from the FHS. Our results provide additional evidence that miRNA expression is partly under genetic control.
Our study also provides multiple lines of evidence in support of a critical role of miRNAs in the pathogenesis of CHD. First, our study identified 15 differentially expressed miRNAs in whole blood, all of which were upregulated in CHD cases. In a previous study, Bidzhekov et al 22 identified 23 differentially expressed miRNAs in atherosclerotic plaques compared with healthy arteries, 20 of which displayed upregulation patterns in atherosclerotic plaques. Therefore, the observed miRNA upregulation patterns in CHD were consistent between our study and that of Bidzhekov et al, 22 suggesting that miRNAs may play an important role in CHD. A similar miRNA upregulation pattern has also been observed in HF studies. In an miRNA microarray analysis by Thum et al, 12 67 miRNAs were upregulated >1.5 fold in failing left ventricles versus normal hearts, whereas 43 miRNAs were downregulated >1.5 fold. 12 In 2 additional studies of HF using plasma samples, Tijsen et al 13 reported that 14 of the 16 differentially expressed miRNAs were upregulated in patients with HF, and 7 of the 14 upregulated miRNAs were validated in an independent HF case-control study. In a study by Goren et al, 40 more downregulated miRNAs (n=13) than upregulated miRNAs (n=10) were reported. Nevertheless, all 4 replicated miRNA (miRNA-423-5p, miRNA-320a, miRNA-22, and miRNA-92b) were upregulated in the HF group. These comparisons highlight a general trend of increased miRNA expression in CHD cases that we observed in our study and that it is largely consistent with previous studies. Second, we detected striking differences in the significant miRNA-mRNA associations (at FDR<0.05) between CHD cases and controls, with 80% of miRNA-mRNA pairs being inversely correlated in CHD cases, compared with 30% of miRNA-mRNA pairs being inversely correlated in controls. These patterns were replicated in independent sets of CHD cases and controls. Recently, Thum et al 12 used bioinformatics methods to predict the binding sites of upregulated miRNAs in HF cases. They found that downregulated mRNAs had more binding sites for the upregulated miRNAs in HF cases. 12 Their results suggest that upregulated miRNAs might suppress mRNA expression in HF. Consistent with this hypothesis, our results support the notion that suppression of mRNAs by miRNAs may also be an important feature in CHD, given the upregulation of miRNAs and the inverse correlation of miRNA-mRNA pairs in CHD cases but not in controls in our study. We hypothesize that striking differences in miRNA-mRNA coexpression patterns between cases and controls represent a useful transcriptomic biomarker of CHD.
Third, by integrating the miR-eSNPs and mRNA-eSNPs identified from our study, as well SNPs as from the CARDIoGRAM CHD GWAS 1 into our analysis, we show that disruptions of miRNA-mRNA coexpression are likely causal for CHD. In this study, we used SNP set enrichment analysis to examine whether a particular miRNA-mRNA coexpression set is significantly enriched for eSNPs that demonstrate low P value association with CHD in the CARDIoGRAM GWAS. 1 Based on the central dogma, genetics is the upstream of gene/ miRNA expression and CHD but unlikely to be altered by CHD. Finding significant enrichment of CHD genetic signals in a given miRNA-mRNA coexpression set, therefore, supports a putative causal role of the miRNA-mRNA pairs. The genetic enrichment signals seen for the case-specific and control-specific coexpression pairs provide evidence that they are putatively causal for CHD, whereas the miRNA signature may not play a causal role in CHD and is likely to be reactive to CHD. The control-specific miRNA-mRNA coexpression pairs (enriched for cell cycle processes) tested putatively causal for CHD when mRNA-eSNPs but not miR-eSNPs were used. Cell cycle pathways have also been recently implicated to be causally associated with coronary artery disease in a separate study. 41 Our observation suggests that tight miRNA-mRNA coexpression patterns that are necessary for normal cell cycle processes may be disrupted in CHD cases. It is possible that this disruption of cell cycle regulation is causal for CHD and that the alteration of miRNA-mRNA coexpression is led by eSNPs regulating mRNA expression rather than eSNPs controlling miRNA expression. On the other hand, the case-specific miRNA-mRNA coexpression pairs were enriched for genes involved in gene silencing by RNA and showed evidence of putative causality via miRNAs. These results support the possibility of a large shift toward negative miRNA-mRNA correlation in CHD cases because of RNAbased regulatory control.
Fourth, we linked miRNAs to a previously identified gene coexpression module that is enriched for genes involved in B-cell functions and enriched for genetic risk polymorphisms associated with CHD. 7 Although macrophages and T cells, but not B cells, are prominent in atherosclerotic lesions in the artery wall, [42] [43] [44] [45] [46] several studies reported that deficiency of B cells either increases 44, 45 or decreases 46 atherosclerosis. A recent study by Hilgendorf et al 47 found that a subset of B cells, termed innate response activator B cells, accumulate in the spleen, bone marrow, and lymph nodes in Apoe −/− mice that also display severe inflammation and atherosclerosis, although they did not detect innate response activator B cells in the aorta. These results suggest that innate response activator B cells do not affect lesions locally but promote atherogenesis in the artery wall through systemic activation of innate immune response. 48 Our B-cell-related findings come from whole blood and also support a systemic role of B cells in atherosclerosis. In this study, we correlated miRNA expression with the first principle component of the CHD gene coexpression module and identified 3 miRNAs correlated with this module. Among these 3 miRNAs, miR-150 has been previously reported to be dysregulated in the setting of myocardial infarction 15 and to be involved in B-cell development. 49, 50 Zhou et al 50 reported that miR-150 participates in early B-cell development by blocking the transition from the pro-B to the pre-B stage. Xiao et al 49 reported that miR-150 controls B-cell differentiation by targeting c-Myb. In our analysis, 5 genes within the CHD causal module were predicted targets of miR-150, among which 2 genes, BTLA and POU2AF1, are involved in B-cell development. These lines of evidence support the hypothesis that a subset of miRNAs mediate gene regulation in the previously identified CHD causal module and the notion that B-cell-centered adaptive immune function plays an important role in CHD. Specifically, perturbations of particular miRNAs, such as miR-150, may lead to dysregulation of B-cell functions and in turn promote atherogenesis and CHD. Future experimental testing of this proposed mechanism is warranted.
Although our study is the largest to examine the inter-relationships among genetic variation and miRNA and mRNA expression, we acknowledge several limitations. First, our investigation focused on whole blood-derived RNA, and further studies in individual cell types and other CHD relevant tissues are necessary to determine the tissue-or cell typespecific genetic control of miRNAs and the precise roles of such genetic control in the gene regulatory networks pertaining to CHD. Nevertheless, as multiple blood constituents, such as oxidized lipids, immune cells, and platelets play important roles in plaque accumulation, rupture, and thrombus formation in the vessel wall, 51 blood has strong pathological relevance to CHD. Indeed, previous whole blood profiling studies of CHD 3-6 have revealed important biological insights. In addition, for epidemiological studies, accessing internal tissues and cell types is challenging, and peripheral whole blood is the most readily available tissue. In our study, the miRNA and mRNA profiling data generated from whole blood mainly reflect the immune and inflammatory processes captured by the various types of leukocytes. We speculate that the large-scale gene regulatory network remodeling we have observed in whole blood from CHD cases represents systemic perturbations in the immune system in both the circulation and the CHD-related tissues. Second, additional molecular interactions, eg, miRNA-miRNA, 52 could be incorporated by using more complicated network analysis models. Last, although our systems biology analysis revealed scores of novel findings and we provided strong evidence from the literature and from validation analyses in independent CHD cases and controls, downstream experimental validation of the potential mechanisms is necessary, but it is out of the scope of our current investigation.
In summary, we systematically analyzed the multidimensional relationships between genetic variation, miRNAs, and mRNAs. We further analyzed miRNA expression profiling and miRNA-mRNA interactomic changes associated with CHD. CHD GWAS 1 results were integrated into our systems analyses to identify the directionality of effects and to infer causality. We observed significant upregulation of 15 miRNAs in CHD cases and a genome-wide miRNA-mRNA correlation shift from positive in controls to negative in CHD cases. We provide evidence supporting the hypothesis that disruption of miRNA-mRNA coexpression by eSNPs that regulate the expression levels of mRNAs or miRNAs may contribute to the development of CHD. We also identified several miRNAs (eg, miR-150) that potentially regulate an mRNA module involved in B-cell-centered adaptive immune function and that they were tested causal for CHD. Overall, our findings support an important role of miRNAs in CHD pathogenesis.
